The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Combined oral contraceptives in the treatment of polycystic ovary syndrome
Abstract
Combined oral contraceptives (COC) are the most often used treatment modality for polycystic ovary syndrome (PCOS). Undisputedly, COC suppress androgen production, thus ameliorating skin androgenic symptoms and improving menstrual dysfunction. On the other hand, there are still many unresolved issues concerning their metabolic effects. COC could decrease insulin sensitivity and deteriorate glucose tolerance, although the negative influence on insulin sensitivity is dependent on other factors (especially obesity) and this need not be expressed in non-obese patients. It is probable that the impairment of glucose tolerance is reversible, as the incidence of diabetes is not increased in past COC users. The effects of COC on the lipid spectrum are dependent on the type of gestagen, but lipid levels usually remain within the reference limits. Combination therapy of COC with weight reduction or insulin sensitizers could further suppress androgen levels and improve metabolic parameters. The establishment of COC after laparoscopic ovarian drilling may further decrease androgen levels. The combination of COC and GnRH analogues is not superior to COC therapy alone. Prospective data about the influence of COC on the risk of diabetes mellitus, coronary artery disease and endometrial cancer in PCOS women are lacking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 4×
“ance to IGT or to DM 2 was described by two groups (Ehrmann et al., 1999; Wang and Norman, 2004), but both studies have a high number of drop-outs (80 and 50%), and so it is difficult to draw any definite conclusion.”
BackgroundInfluentialVelazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
Mortality of Women with Polycystic Ovary Syndrome at Long-term Follow-up
Pierpoint, T., McKeigue, P. M., Isaacs, A. J., Wild, S. H., & Jacobs, H. S. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00035-3 · Cited by 504
Ehrmann, D. A., Sturis, J., Byrne, M. M., Karrison, T., Rosenfield, R. L., & Polonsky, K. S. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118064 · Cited by 426
Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232003 · Cited by 417
Oral Contraceptives and the Risk of Myocardial Infarction
Tanis, B. C., van den Bosch, M. A. A. J., Kemmeren, J. M., Cats, V. M., Helmerhorst, F. M., Algra, A., van der Graaf, Y., & Rosendaal, F. R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003216 · Cited by 367
Mooy, J. M., Grootenhuis, P. A., de Vries, H., Kostense, P. J., Popp-Snijders, C., Bouter, L. M., & Heine, R. J. (1996) · Diabetologia · doi:10.1007/bf00418345 · Cited by 344
Norman, R. J., Masters, L., Milner, C. R., Wang, J. X., & Davies, M. J. (2001) · Human Reproduction · doi:10.1093/humrep/16.9.1995 · Cited by 341
The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women
MORTOLA, J. F., & YEN, S. S. C. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-3-696 · Cited by 311
Clausen, J. O., Borch-Johnsen, K., Ibsen, H., Bergman, R. N., Hougaard, P., Winther, K., & Pedersen, O. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118903 · Cited by 259
Effect of four different oral contraceptives on various sex hormones and serum-binding globulins
Wiegratz, I., Kutschera, E., Lee, J. H., Moore, C., Mellinger, U., Winkler, U. H., & Kuhl, H. (2003) · Contraception · doi:10.1016/s0010-7824(02)00436-5 · Cited by 239 · cited 3×
“Significant differences in SHBG changes among preparations with various gestagens using the same dose of EE were repeatedly presented (van der Vange et al., 1990; Wiegratz et al., 2003).”
BackgroundMethodKjos, S. L. (1998) · JAMA · doi:10.1001/jama.280.6.533 · Cited by 174
Acién, P., Quereda, F., Matallı́n, P., Villarroya, E., López-Fernández, J. A., Acién, M., Mauri, M., & Alfayate, R. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00184-3 · Cited by 170
Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.
Korytkowski, M. T., Mokan, M., Horwitz, M. J., & Berga, S. L. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.11.7593446 · Cited by 140
Wiegratz, I., Jung-Hoffmann, C., & Kuhl, H. (1995) · Contraception · doi:10.1016/0010-7824(95)00098-u · Cited by 115 · cited 3×
“The other mechanism discussed is the influence on adrenal steroidogenesis (Wiegratz et al., 1995), which is assumed due to observed changes in the concentration”
BackgroundSabuncu, T., Harma, M., Harma, M., Nazligul, Y., & Kilic, F. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)02162-9 · Cited by 78
Gaspard, U., Scheen, A., Endrikat, J., Buicu, C., Lefebvre, P., Gerlinger, C., & Heithecker, R. (2003) · Contraception · doi:10.1016/s0010-7824(02)00537-1 · Cited by 72
Rosen, M. P., Breitkopf, D. M., & Nagamani, M. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.294 · Cited by 56
Is insulin resistance an essential component of PCOS?: The influence of confounding factors
Cibula, D. (2004) · Human Reproduction · doi:10.1093/humrep/deh137 · Cited by 43
Self-citation
Cited by
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61345-2 · Cited by 1,360
Franks, S. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.1.89 · Cited by 806
Costello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197
Metadata
- Authors
- Vrbíková, J., & Cibula, D.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05-01
- Volume
- 11
- Issue
- 3
- Pages
- 277-291
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2119213719
- Cited by
- 163
- References
- 23
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.